A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Public ClinicalTrials.gov record NCT03336216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
Study identification
- NCT ID
- NCT03336216
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 205 participants
Conditions and interventions
Conditions
Interventions
- Cabiralizumab Biological
- Nab-paclitaxel Drug
- Onivyde Drug
- Nivolumab Biological
- Fluorouracil Drug
- Gemcitabine Drug
- Oxaliplatin Drug
- Leucovorin Drug
- Irinotecan Hydrochloride Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2017 (Actual)
- Primary completion
- Jun 1, 2023 (Actual)
- Completion
- Jun 1, 2023 (Actual)
- Last update posted
- Jul 23, 2024
2017 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Rochester, Minnesota | Phoenix | Arizona | 85054 | — |
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| Local Institution - 0007 | Los Angeles | California | 90095 | — |
| University Of Colorado | Aurora | Colorado | 80045 | — |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0001 | Baltimore | Maryland | 21287 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute. | Boston | Massachusetts | 02114 | — |
| Local Institution - 0010 | Boston | Massachusetts | 02114 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Local Institution - 0012 | New York | New York | 10016 | — |
| Local Institution - 0005 | New York | New York | 10065 | — |
| Local Institution - 0006 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0009 | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology Chattanooga | Nashville | Tennessee | 37203 | — |
| Local Institution - 0013 | Dallas | Texas | 75390 | — |
| Local Institution - 0011 | Houston | Texas | 77030 | — |
| University Of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03336216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03336216 live on ClinicalTrials.gov.